Effects of Empagliflozin on Sexual Function, Testicular Histology and Biochemical Parameters in Young and Middle-Aged Diabetic Rats of Type2

Background: Empagliflozin, selective glucose-sodium inhibitor of the latest drugs in the treatment of type 2 diabetes. Diabetes induced hypogonadism disrupts sexual function. There is a direct relationship between reducing blood glucose and reduced libido. In this project, the anti-diabetic drug Empagliflozin in addition to treatment has been studied, in terms of effect on sexual function. Methods: Type 2 diabetes with injection of 60 mg/kg streptozotocin per body weight was create intraperitoneally. The primary diabetes was treated with two doses of 10 and 25 mg/kg Empagliflozin per body weight. Sexual hormones, biochemical parameters and lipid profile were measured. Evaluation of Sperm parameters and morphological studies were performed on testicular tissue, pancreas and epididymis. Data were analyzed by one-way ANOVA in SPSS software version 22 and P˂0.05 was considered as a significant level. Results: Empagliflozin significantly increases the quality, survival and natural state of sperm head and tail. Empagliflozin reduces weight in diabetic rats. Empagliflozin Without increasing hyperglycemia by reducing blood glucose affects steroidogenesis, maintains fertility strength in testicles, and increases the level of sex hormones. Empagliflozin significantly increases insulin secretion. Empagliflozin maintains and integrity of pancreatic beta cells. Empagliflozin has no effect on lipid profile. Conclusion: Empagliflozin in addition positive effects on the treatment of diabetes in the early stage improves sexual function in adult rats.